GLUCAGON KIT

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

GLUCAGON (RECOMBINANT DNA ORIGIN)

Предлага се от:

ELI LILLY CANADA INC

АТС код:

H04AA01

INN (Международно Name):

GLUCAGON

дозиране:

1MG

Лекарствена форма:

KIT

Композиция:

GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

1 ML

Вид предписание :

Schedule D

Терапевтична област:

GLYCOGENOLYTIC AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0142861001; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2023-12-18

Данни за продукта

GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................